Arvind Remedies Peer Comparison

NSE: ARVINDREM | BSE: 531823

₹4.70

₹-0.24 (-4.86%)

As on 13-Jun-2016IST

Market cap

₹32 Cr

Revenue (TTM)

₹12 Cr

P/E Ratio

P/B Ratio

-0.2

Div. Yield

0 %

Edit

	Arvind Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Market cap (₹ Cr)	32	30,629	31,066	26,421	25,078
Revenue (₹ Cr)	12	3,564	1,593	5,155	1,936
Net Profit (₹ Cr)	-137.36	414.00	438.64	674.76	288.22
Net Margin (%)	-1,121.27	11.23	27.16	11.86	14.79
RoE (%)	--	8.38	25.02	9.03	29.77
Price to Earnings	--	74.89	70.74	--	87.01
Price-To-Book	-0.20	6.08	16.73	3.24	18.68

Income Statement (₹ Cr)

	Arvind Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Operating Revenue	962.68	4,830.36	76.11	--	41.58
Total Income	963.22	4,914.64	76.68	--	41.73
Total Expenditure	781.32	3,850.53	69.99	--	30.00
EBITDA	181.36	979.83	6.12	--	11.59
Depreciation	14.34	139.92	0.80	--	3.35
EBIT	167.03	839.91	5.32	--	8.24
Interest	78.51	83.35	1.58	--	2.34
Other Income	0.54	84.28	0.56	--	0.14
Exceptional Items	--	49.83	--	--	--
Profit before Tax	89.05	890.67	4.31	--	6.04
Provision for Tax	28.69	47.88	1.44	--	1.54
Profit after Tax	60.36	842.79	2.86	--	4.50

	Arvind Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Shareholder's Funds	283.06	3,581.47	10.77	--	44.83
Minority Interest	4.85	136.17	--	--	--
Non-Current Liabilities	288.00	1,161.18	1.29	--	10.36
Current Liabilities	547.46	1,743.20	26.33	--	21.34
Total Liabilities	1,123.36	6,622.02	38.71	--	76.53

	Arvind Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Non-Current Assets	433.26	3,266.10	7.38	--	51.75
Current Assets	690.11	3,355.92	31.01	--	24.78
Total Assets	1,123.36	6,622.02	38.71	--	76.53
Total Debt*	640.97	1,906.08	12.17	--	21.09
Net Current Assets	142.65	1,612.72	4.68	--	3.44
Contingent Liabilities	1.20	267.40	--	--	4.70

	Arvind Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Cash From Operating Activities	-65.08	1,476.29	-0.21	--	6.29
Cash Flow from Investing Activities	-24.64	-851.62	-2.00	--	-5.46
Cash from Financing Activities	71.24	-601.32	2.17	--	-0.58
Net Cash Inflow / Outflow	-18.48	23.35	-0.04	--	0.25

	Arvind Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
ROCE (%)	20.48	18.98	29.97	--	13.38
ROE (%)	26.81	30.04	30.26	--	19.08
ROA (%)	6.07	13.36	8.85	--	6.16
EBIT Margin (%)	18.90	22.03	8.78	--	28.21
Net Margin (%)	6.27	17.15	3.74	--	10.78
Cash Profit Margin (%)	7.33	20.32	4.81	--	18.86

	Arvind Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Revenue Growth (%)	36.34	-13.89	37.10	--	12.11
EBIT Growth (%)	28.76	-49.66	30.95	--	21.82
Net Profit Growth (%)	34.25	-46.64	39.55	--	58.36
EPS Growth (%)	-4.56	-56.04	39.55	--	58.36
Book Value Growth (%)	57.80	36.37	32.03	--	21.09

	Arvind Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Price / Earnings	5.03	6.59	0.00	--	0.00
Price / Book Value	1.07	1.55	0.00	--	0.00
Dividend Yield (%)	1.85	2.19	--	--	--
EV/EBITDA	5.11	5.73	2.02	--	3.52
Market Cap (₹ Cr)	293.96	5,016.58	0.00	--	0.00

	Arvind Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debt to Equity	2.33	0.54	1.13	--	0.47
Short term debt to equity ratio	1.22	0.06	0.84	--	0.23
Current Ratio	1.26	1.93	1.18	--	1.16
Quick Ratio	0.90	1.36	0.75	--	1.11
Interest Coverage	2.13	11.69	3.73	--	3.58

	Arvind Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debtors to sales (%)	36.39	9.96	17.81	--	33.85
Asset Turnover	1.02	0.77	2.35	--	0.57
Receivable days	109.13	54.33	58.46	--	106.93
Inventory Days	58.18	77.43	41.85	--	10.49
Payable days	41.26	120.43	91.25	--	213.33
Cash Conversion Cycle	126.04	11.32	9.06	--	-95.91

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.